Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Pain 19Neoplasms 18Cancer Pain 6Breast Neoplasms 5Breakthrough Pain 5Prostatic Neoplasms 4Lung Neoplasms 4Colonic Neoplasms 4Agnosia 4Rectal Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Chronic Pain 3Uterine Cervical Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain, Postoperative 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Burns 2Anemia, Sickle Cell 2post laminectomy syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Burns × Fentanyl × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡